Tocilizumab (TCZ), an interleukin-6-receptor inhibitor (IL-6Ri), demonstrated significant efficacy in Phase 2 and 3 trials [16, 17], leading to its approval in the USA and Europe for the treatment of patients with GCA [18–20]. Here, IL6R is linked to temporal arteritis.